TB-500 (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Loading calls for 2 to 4 injections per week and maintenance for 1 to 2, never daily. TB-500 works by mass action binding: milligram boluses are needed to bind enough G-actin to raise the cellular reserve meaningfully, and once those reserves exist the biological effect persists for days even though the peptide itself clears in hours (half life 0.5 to 2.1 hours intravenous). Actin pools do not vanish when TB-500 clears; they stay available until the cell draws on them, which is why 2 to 4 mg given 2 to 3 times weekly outperforms smaller daily dosing. Peak concentration drives the binding event and the downstream effect sustains itself between doses. Either subcutaneous or intramuscular works, with intramuscular often preferred for deeper musculoskeletal injuries and subcutaneous near the injury site standard for tendon and superficial work; for hard to reach areas such as deep hip or spine, abdominal or thigh injection is the practical fallback. The twice weekly cadence is practitioner derived convention aligned with this mechanism, not formal pharmacokinetic modeling.

Results Timeline

Sequence described in the research record. Individual response varies.

• Weeks 1 to 2: morning stiffness and first step pain decrease.
• Weeks 3 to 4: range of motion improves and tissue planes separate properly.
• Weeks 5 to 8: eccentric loading tolerance increases and progressive loading becomes possible.
• Acute injuries respond faster; chronic injuries often need the full 6 to 8 week course plus BPC-157.

Reconstitution Steps

1. Draw 1.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe. 2 mg = 20 units (0.20 mL); 4 mg = 40 units (0.40 mL).

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at minus 20 °C (minus 4 °F) in dry, dark conditions; stable for 12 months or longer.
• Reconstituted: refrigerate at 2 to 8 °C (35.6 to 46.4 °F) and avoid repeated freezing and thawing.

• Allow vials to reach room temperature before opening to reduce condensation uptake.
• Keep vials protected from light and label each one with the reconstitution date and the concentration, 10 mg/mL.

Supplies Needed

The math below is based on a standard six week course: four weeks of loading at 4 mg per week, then two weeks of maintenance at 2 mg per week.

Peptide Vials (TB-500, 10 mg vial):

• That course uses roughly 20 mg in total, which works out to about 2 vials at 10 mg each. An eight week course at higher loading, 6 mg per week then 4 mg per week for roughly 36 mg, runs closer to 4 vials.

Insulin Syringes (U-100):

• Per week: 2 to 4 syringes during loading and 1 to 2 during maintenance, one syringe per injection. At 10 mg/mL the largest listed dose is 40 units, so a 50 unit U-100 syringe covers every dose in this protocol.
• Full six week course: about 12 to 16 syringes. Two to three cycles per year works out to roughly 36 to 48.

Bacteriostatic Water (10 mL bottles):

• 1.0 mL of bacteriostatic water per 10 mg vial, so a single 10 mL bottle covers about 10 vials.

Alcohol Swabs:

• Two swabs per injection, one for the vial stopper and one for the skin.
• Full six week course: about 24 to 32 swabs, comfortably inside one 100 count box.

Important Notes

Practical considerations for consistency and safety.

• Labeling reality: most vendor product sold as TB-500 is actually full length TB-4. Doping control analysis of commercial vials confirmed this. Verification is on the COA: about 4,900 Da or 43 amino acids means TB-4, about 800 Da or 7 amino acids means the LKKTETQ fragment, and where the COA does not specify, TB-4 is the safe assumption. The two are not mechanistically identical, since TB-4 carries the antifibrotic Ac-SDKP site at positions 1 to 4 that the fragment lacks, so TB-4 is what the evidence supports when scar reduction is the goal.
• Not a daily peptide. The mechanism is mass action: TB-500 binds G-actin monomers one to one, so milligram boluses are required to build the reserve pool and smaller daily doses do not reach the binding threshold. Doses of 2 to 4 mg given 2 to 3 times weekly outperform daily dosing.
• The loading plus maintenance structure is the protocol, not an optional refinement. Loading across weeks 1 to 4 concentrates dosing during the early to mid remodeling phases while tissue architecture is being established, and maintenance across weeks 5 to 8 supports collagen organization. Skipping loading or running a flat dose continuously misses that architectural window. A cycle of 6 to 8 weeks is standard, followed by 4 to 8 weeks off before repeating.
• Injection site matters even though the peptide does not stay local. TB-500 enters systemic circulation rapidly regardless of site, but local injection produces a higher first pass concentration spike before dilution. Targeted delivery has been decisive in animal work: free systemic TB-4 at the same total dose produced zero functional improvement in cardiac repair, while sustained local release reached 93% wound closure in diabetic rats.
• Absolute contraindications in the master protocol: active cancer or malignancy within 2 years, since TB-500 promotes angiogenesis and cell migration; pregnancy or breastfeeding; proliferative retinopathy, where added angiogenesis may worsen pathology; and planned or recent surgery within 2 weeks. Relative contraindications: concurrent corticosteroid use, severe cardiovascular disease, active autoimmune conditions, and therapeutic anticoagulation. Reported side effects are occasional injection site reactions and rare mild lethargy lasting 12 to 24 hours.
• Regulatory Note: TB-500 is a research compound with no approved drug status; the only formal human safety work used recombinant TB-4 rather than the synthetic product most vendors ship, and those vendor products have not been independently characterized in human safety studies. It is prohibited at all times in sport under WADA category S0, the class covering substances with no approval for human therapeutic use, testing can detect TB-500 metabolites, and the NFL, NBA, MLB, and FIFA have adopted similar restrictions.

How This Works

TB-500 and TB-4 share the actin binding domain LKKTETQ but are not mechanistically identical, since TB-4 carries active sites the fragment does not. The shared primary mechanism is actin sequestration. Actin inside a cell exists in two states, free monomers in the cytoplasm (G-actin) and assembled filaments (F-actin), and the LKKTETQ sequence binds G-actin one to one, preventing premature polymerization and maintaining a reserve pool that can be deployed quickly. Without that reserve, cells respond sluggishly to repair signals because they must manufacture new actin rather than draw on inventory. The practical result is that fibroblasts migrate efficiently into injured tendons, endothelial cells extend into damaged zones to form new vessels, and keratinocytes advance across wound surfaces; the rate limiting step shifts from whether the cell can move to where it should go. A 2024 finding adds nuance: TB-500 undergoes serial C-terminal cleavage after injection and one metabolite, Ac-LKKTE, shows independent wound healing activity, suggesting the peptide functions partly as a prodrug and helping explain why activity persists beyond its short plasma half life. Mechanisms belonging to TB-4 alone include antifibrotic Ac-SDKP release through a meprin-alpha then POP cleavage cascade that suppresses TGF-beta and Smad2/3 and blocks myofibroblast differentiation, macrophage polarization from M1 inflammatory to M2 reparative, the antiapoptotic fragment 1 to 15 that inhibits caspases 2, 3, 8, and 9, and ILK, PINCH, and Akt cardiac signaling. This is also why TB-500 complements BPC-157: BPC-157 upregulates VEGF as the signal to build vessels, while TB-500 lets endothelial cells physically move and organize into functional capillaries.

Benefits & Side Effects

Observations from the published record.

• SEER-1 Phase 3 in neurotrophic keratopathy (n=18): 60% complete healing versus 12.5% on placebo, and 50% maintained healing versus 0% at Day 43 (p=0.0359). The cornea carries no blood vessels, so any healing effect has to come from direct cellular action, which removes the perfusion confound.
• Phase 1 safety (Wang 2021, n=84): recombinant TB-4 at doses up to 25 mcg per kg daily for 10 days produced no serious adverse events and no dose limiting toxicity, a tolerance roughly 100 fold above standard protocol doses. That trial used recombinant TB-4, not synthetic TB-500.
• Chronic venous ulcer trial (n=72): a 0.03% thymosin beta-4 gel produced about 25% complete wound closure at 3 months in wounds that had resisted conventional treatment.
• Diabetic wound healing in rats: a collagen and chitosan scaffold delivering TB-4 over 12 days reached 93% wound closure at day 21, with faster resurfacing, organized collagen, and increased CD31 positive vessel density.
• Cardiac repair in preclinical mouse models of myocardial infarction: TB-4 activated the ILK pathway, promoted cardiac cell migration and survival, and influenced epicardial progenitor cells, with targeted delivery clearly outperforming free systemic dosing.
• Side effects reported in practice are occasional injection site reactions, which rotating sites and warming the vial before injection can reduce, and rare mild lethargy lasting 12 to 24 hours, best handled with hydration and by scheduling the injection before a rest day.

Lifestyle Factors

Complementary strategies for best outcomes.

• Progressive loading is the mechanical signal that tells migrating cells where to organize; TB-500 enables the movement, but without loading the repair tissue is undirected.
• Sleep of 7 to 9 hours matters directly, since tissue remodeling and organization happen during sleep and sleep debt undermines the protocol.
• Protein at 1.0 to 1.2 g per kg of body weight supplies substrate for collagen and matrix deposition, and adequate hydration supports matrix mobility and collagen quality.
• Minimizing NSAIDs, corticosteroids, and alcohol during a cycle avoids suppressing the same repair mechanisms the protocol is meant to support; passive immobilization beyond what is medically necessary should also be avoided.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Goldstein AL et al. Thymosin beta-4 actin sequestering mechanism (Trends Mol Med, 2005).
2. Sosne G et al. SEER-1 Phase 3 thymosin beta-4 in neurotrophic keratopathy (Int J Mol Sci, 2022).
3. Wang D et al. Phase 1 safety of recombinant human thymosin beta-4, n=84 (Ann Transl Med, 2021).
4. Yang Y et al. TB-500 serial C-terminal cleavage and Ac-LKKTE metabolite wound healing activity (Drug Test Anal, 2024).
5. Esposito S et al. TB-500 identification and commercial product mislabeling (Drug Test Anal, 2012).
6. Bock-Marquette I et al. Thymosin beta-4 ILK pathway and cardiac cell migration (Nature, 2004).